PYRAZINE DERIVATIVES, USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS Russian patent published in 2011 - IPC C07D401/04 C07D403/04 C07D405/14 C07D409/14 C07D417/04 C07D417/14 A61K31/497 A61K31/506 A61P11/06 A61P9/12 A61P3/10 A61P37/00 

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (I): where: A is a monocyclic or polycyclic aryl or heteroaryl group, where the heteroaryl radical denotes a 5-10-member cyclic system containing at least one heteroaromatic ring and containing at least one heteroatom selected from O, S and N; optionally substituted with one or more substitutes independently selected from a group comprising halogen atoms, C_1-4alkyl, C_3-8cycloalkyl, C_3-8cycloalkyl-C_1-4alkyl, C_1-4alkoxy and a hydroxyl group; B is a monocyclic nitrogen-containing heteroaryl group, where the heteroaryl radical denotes a 5-6-member heteroaromatic ring containing at least one heteroatom selected from S and N; optionally substituted with one or more substitutes selected from a group consisting of halogen atoms, C_1-4alkyl, C_3-8cycloalkyl, C_3-8cycloalkyl-C_1-4alkyl, aryl and C_1-8alkylthio; either a) R¹ is a group of formula: -L-(CR'R")n-G, where L is a binding group selected from a group consisting of a direct bond, -(CO)-, -(CO)NR'- and -SO₂-; R' and R" is independently selected from hydrogen atoms; n assumes values from 0 to 1; and G is selected from a group consisting of a hydrogen atom and C_1-4alkyl, aryl, heteroaryl, where the heteroaryl radical denotes a 5-6-member heteroaromatic ring containing at least one heteroatom selected from O, S and N; C_3-8cycloalkyl and saturated heterocyclic groups, where heterocyclic group denotes a non-aromatic saturated 6-member carbocyclic ring in which one or two carbon atoms are substituted with a N heteroatom; where alkyl, C_3-8cycloalkyl, aryl or heteroaryl groups are unsubstituted or substituted with one or more substitutes selected from halogen atoms; and R² is a group selected from hydrogen atoms, halogen atoms and C_1-4alkyl, C_2-5alkynyl, C_1-4alkoxy, -NH₂ and cyano groups, where alkyl and alkynyl groups may be unsubstituted or substituted with one aryl group; or b) R², R¹ and -NH- group to which R¹ is bonded form a group selected from groups of formulae and , where: R^a is selected from a hydrogen atom or groups selected from C_1-4alkyl, C_3-8cycloalkyl, aryl, aryl-C_1-4alkyl, heteroaryl, where the heteroaryl radical denotes a 5-6-member heteroaromatic ring containing at least one heteroatom selected from O and N; saturated heterocyclic rings, where the heterocyclic group denotes a non-aromatic saturated 6-member carbocyclic ring in which one carbon atom is substituted with a heteroatom selected from O and N; and C_1-4alkylthio; where the aryl or heteroaryl groups are unsubstituted or substituted with one or more groups selected from halogen atoms, cyano group, trifluoromethoxy and carbamoyl; R^b denotes hydrogen; and pharmaceutically acceptable salts thereof and N-oxides; provided that the compound is not selected from N-[6-(1-methyl-1H-indol-3-yl)-5-pyridin-2-ylpyrazin-2-yl]benzamide, N-[3-ethoxycarbonyl-6-(1-methyl-1H-indol-3-yl)-5-pyridin-2-ylpyrazin-2-yl]benzamide, and N-[3-ethoxycarbonyl-6-(1-methyl-1H-indol-3-yl)-5-pyridin-2-ylpyrazin-2-yl]formamide. The invention also relates to a pharmaceutical composition, use of compounds in any of claims 1-20, a method of treating a subject, as well as a composite product.

EFFECT: obtaining novel biologically active compounds having adenosine A_2B receptor antagonist activity.

27 cl, 160 ex, 2 tbl